TY  - GEN
AU  - Dijkgraaf,E M
AU  - Santegoets,S J A M
AU  - Reyners,A K L
AU  - Goedemans,R
AU  - Wouters,M C A
AU  - Kenter,G G
AU  - van Erkel,A R
AU  - van Poelgeest,M I E
AU  - Nijman,H W
AU  - van der Hoeven,J J M
AU  - Welters,M J P
AU  - van der Burg,S H
AU  - Kroep,J R
TI  - A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer
SN  - 1569-8041
PY  - 2016///0707
KW  - Adenocarcinoma, Clear Cell
KW  - blood
KW  - Adenocarcinoma, Mucinous
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Biomarkers, Tumor
KW  - CA-125 Antigen
KW  - Carboplatin
KW  - Cystadenocarcinoma, Serous
KW  - Dose-Response Relationship, Drug
KW  - Doxorubicin
KW  - Endometrial Neoplasms
KW  - Enzyme-Linked Immunosorbent Assay
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Interferon alpha-2
KW  - Interferon-alpha
KW  - Interferon-gamma
KW  - Interleukin-6
KW  - Middle Aged
KW  - Neoplasm Invasiveness
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Ovarian Neoplasms
KW  - Polyethylene Glycols
KW  - Prognosis
KW  - Receptors, Interleukin-6
KW  - antagonists & inhibitors
KW  - Recombinant Proteins
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdv309
ER  -